Mephedrone and other cathinones

Current Opinion in Psychiatry

Volumn 27, Issue 4, 2014, Pages 256-262

  Zawilska, Jolanta B ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

designer drugs; mephedrone; psychostimulants; synthetic cathinones

Indexed keywords

3,4 METHYLENEDIOXYPYROVALERONE; 4' METHYLMETHCATHINONE; CATHINONE; CREATINE KINASE; CREATININE; DOPAMINE; PYROVALERONE; UNCLASSIFIED DRUG; ALKALOID; CENTRAL STIMULANT AGENT; DESIGNER DRUG; METHAMPHETAMINE;

ACUTE KIDNEY FAILURE; ACUTE LIVER FAILURE; ANIMAL BEHAVIOR; ANOREXIA; ANXIETY DISORDER; AUDITORY HALLUCINATION; AUTOMUTILATION; BEHAVIOR DISORDER; BLURRED VISION; BODY WEIGHT DISORDER; BRUXISM; CARDIOMYOPATHY; CATATONIA; COGNITION; COGNITIVE DEFECT; COMPARTMENT SYNDROME; CONFUSION; CONVULSION; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DELUSION; DEPRESSION; DISSEMINATED INTRAVASCULAR CLOTTING; DIZZINESS; DOPAMINE UPTAKE; DRUG ABUSE; DRUG DEPENDENCE; DRUG DISTRIBUTION; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG OVERDOSE; DRUG TOLERANCE; DYSPHORIA; DYSTHYMIA; EMOTIONAL DISORDER; EPISTAXIS; HEALTH DISPARITY; HEART ARREST; HEART PALPITATION; HUMAN; HYPERHIDROSIS; HYPERKALEMIA; HYPERTENSION; HYPERTHERMIA; HYPONATREMIA; INSOMNIA; LOCOMOTION; MEMORY DISORDER; MEN WHO HAVE SEX WITH MEN; MENTAL DISEASE; METABOLIC ACIDOSIS; MULTIPLE ORGAN FAILURE; MYDRIASIS; NAUSEA AND VOMITING; NECROTIZING FASCIITIS; NEUROTOXICITY; NIGHTMARE; NONHUMAN; NOSE IRRITATION; PANIC; PARANOIA; PATIENT EDUCATION; PERCEPTION DISORDER; PERSONALITY DISORDER; POLYDIPSIA; PSYCHOSIS; PUBLIC HEALTH PROBLEM; RESTLESSNESS; REVIEW; RHABDOMYOLYSIS; SEIZURE; SEXUAL HEALTH; SIDE EFFECT; SINUS TACHYCARDIA; SUICIDE ATTEMPT; SWEAT GLAND DISEASE; TACHYCARDIA; THORAX PAIN; TREMOR; URINE RETENTION; VISUAL HALLUCINATION; WITHDRAWAL SYNDROME; XEROSTOMIA; ANALOGS AND DERIVATIVES;

ALKALOIDS; CENTRAL NERVOUS SYSTEM STIMULANTS; DESIGNER DRUGS; HUMANS; METHAMPHETAMINE;

EID: 84901844227     PISSN: 09517367     EISSN: 14736578     Source Type: Journal    
DOI: 10.1097/YCO.0000000000000066     Document Type: Review

References (75)

1. Zawilska JB, Wojcieszak J. Designer cathinones: an emerging class of novel recreational drugs. Forensic Sci Int 2013; 231:42-53.
2. Valente MJ, Guedes de Pinho P, de Lourdes Bastos M, et al. Khat and synthetic cathinones: a review. Arch Toxicol 2014; 88:15-45.
3. Marinetti LJ, Antonides HM. Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. J Analyt Toxicol 2013; 37:135-146.
4. Leffler AM, Smith PB, de Armas A, Dorman FL The analytical investigation of synthetic street drugs containing cathinone analogs. Forensic Sci Int 2014; 234:50-56.
5. Seely KA, Patton AL, Moran CL, et al. Forensic investigation of K2, Spice, and 'bath salt' commercial preparations: a three-year study of new designer drug products containing synthetic cannabinoid, stimulant, and hallucinogenic compounds. Forensic Sci Int 2013; 233:416-422.
6. Helander A, Beck O, Hägerkvist R, Hulten P. Identification of novel psychoactive drug use in Sweden based on laboratory analysis: initial experiences from the STRIDA project. Scand J Clin Lab Invest 2013; 73:400-406.
7. Schifano F, Albanese A, Fergus S, et al. Mephedrone (4-methylmethcathi- none; 'meow meow'): chemical, pharmacological and clinical issues. Psy-chopharmacology (Berl) 2011; 214:593-602.
8. Brunt TM, Poortman A, Niesink RJ, van den Brink W. Instability of the ecstasy market and a new kid on the block: mephedrone. J Psychopharmacol 2011; 25:1543-1547.
9. McElrath K, O'Neill C. Experiences with mephedrone pre-and post-legislative control: perceptions of safety and sources of supply. Int J Drug Policy 2011; 22:120-127.
10. Chen C, Kostakis C, Irvine RJ, White JM. Increases in use of novel synthetic stimulant are not directly linked to decreased use of 3, 5-methylenedioxy-N-methylamphetamine (MDMA). Forensic Sci Int 2013; 231:278-283.
11. Moore K, Dargan K, Wood PI, Measham DM. Do novel psychoactive sub as stance displace established club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine. Eur Addict Res 2013; 19:276-283.
12. Martínez-Clemente J, López-Arnau R, Carbó M, et al. Mephedrone pharmacokinetics after intravenous and oral administration in rats: relation to pharmacodynamics. Psychopharmacol 2013; 229:295-306.
13. López-Arnau R, Martínez-Clemente J, Carbó Ml, et al. An integrated pharmacokinetic and pharmacodynamic study of a new drug of abuse, methy-lone, a synthetic cathinone sold as 'bath salts'. Biol Psychiatry 2013; 45:64-72.
14. Fonsart J, Menet MC, Debray M, et al. Sprague-Dawley rats display sex-linked differences in the pharmacokinetics of 3, 4- methylenedioxymethamphetamine (MDMA) and its metabolite 3, 4- methylenedioxyamphetamine (MDA). Toxicol Appl Pharmacol 2009; 241:339-347.
15. Concheiro M, Baumann MH, Scheidweiler KB, et al. Nonlinear pharmacokinetics of (±)3, 4-methylenedioxymethamphetamine (MDMA) and its pharmacodynamic consequences in the rat. Drug Metab Dispos 2014; 42:119-125.
16. Aarde SM, Angrish D, Barlow DJ, et al. Mephedrone (4-methylmethcathinone) supports intravenous self-administration in Spraque-Dawley and Wistar rats. Addiction Biol 2013; 18:786-799.
17. Simmler LD, Buser TA, Donzelli M, et al. Pharmacological characterization of designer cathinones in vitro. Br J Pharmacol 2013; 168:458-470.
18. Chu T, Kumagai Y, DiStefano EW, Cho AK. Disposition of methylenediox-ymethamphetamine and three metabolites in the brains of different rat strains and their possible roles in acute serotonin depletion. Biochem Pharmacol 1996; 51:789-796.
19. Khreit OI, Grant MH, Zhang T, et al. Elucidation of the phase I and phase II metabolic pathways of (±)-4'-methylmethcathinone (4-MMC) and (±)-4'-(trifluoromethyl)methcathinone (4-TFMMC) in rat liver hepatocytes using LC-MS and LC-MS. J Pharm Biomed Anal 2013; 72:177-185.
20. Meyer MR, Vollmar C, Schwaninger AE, et al. Newcathinone-derived designer drugs 3-bromomethcathinone and 3-fluoromethcathinone: studies on their metabolism in rat urine and human liver microsomes using GC-MS and LC-high-resolution MS and their detectability in urine. J Mass Spectrom 2012; 47:253-262.
21. Meyer MR, Du P, Schuster F, Maurer HH. Studies on the metabolism of the a-pyrrolidinophenone designer drug methylenedioxypyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. J Mass Spectrom 2010; 45:1426-1442.
22. Pedersen AJ, Reitzel LA, Johansen SS, Linnet K. In vitro metabolism studies on mephedrone and analysis of forensic cases. Drug Test Anal 2013; 5:430-438.
23. Hadlock GC, Webb KM, McFadden LM, et al. 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse. J Pharmacol Exp Ther 2011; 339:530-536.
24. López-Arnau R, Martínez-Clemente J, Pubill D, et al. Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone. Br J Pharmacol 2012; 167:407-420.
25. Martínez-Clemente J, Escubedo E, Pubill D, Camarasa J. Interaction of mephedrone with dopamine and serotonin targets in rats. Eur Neuropsycho-pharmacol 2012; 22:231-236.
26. Cameron K, Kolanos R, Verkariya R, et al. Mephedrone and methylenediox-ypyrovalerone (MDPV), major constituents of 'bath salts', produce opposite effects at the human dopamine transporter. Psychopharmacology (Berl) 2013; 227:493-499.
27. Eshleman AJ, Wolfrum KM, Hatfield MG, et al. Substituted methcathinones differ in transporter and receptor interactions. Biochem Pharmacol 2013; 85:1803-1815.
28. Baumann MH, Partilla JS, Lehner KR, et al. Powerful cocaine-like actions of 3, 4-methylenedioxypyrovalerone (MDPV), a principal constituent of psycho-active 'bath salts' products. Neuropsychopharmacology 2013; 38:552-562.
29. Motbey CP, Hunt GE, Bowen MT, et al. Mephedrone (4-methylmethcathi-none, 'meow'): acute behavioural effects and distribution of Fos expression in adolescent rats. Addict Biol 2012; 17:409-422.
30. Kehr J, Ichinose F, Yoshitake S, et al. Mephedrone, compared with MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and 5-HT levels in nucleus accumbens of awake rats. Br J Pharmacol 2011; 164:1949-1958.
31. Angoa-Pérez M, Kane MJ, Francescutti DM, et al. Mephedrone, an abused psychoactive component of 'bath salts' and methamphetamine congener, does not cause neurotoxicity to dopamine nerve endings of the striatum. J Neurochem 2012; 120:1097-1107.
32. den Hollander B, Rozov S, Linden AM, et al. Long-term cognitive and neurochemical effects of 'bath salts' designer drugs methylone and mephe-drone. Pharmacol Biochem Behav 2013; 103:501-509.
33. Shortall SE, Macerola AE, Swaby RT, et al. Behavioural and neurochemical comparison of chronic intermittent cathinone, mephedrone and MDMA administration to the rat. Eur Neuropsychopharmacol 2013; 23:1085-1095.
34. Angoa-Pérez M, Kane MJ, Herrera-Mundo N, et al. Effects of combined treatment with mephedrone and methamphetamine or 3, 4-methylenedioxy-meth-amphetamine on serotonin nerve endings of the hippocampus. Life Sci 2014; 97:31-36.
35. Angoa-Pérez M, Kane MJ, Briggs DI, et al. Mephedrone does not damage dopamine nerve endings of the striatum, but enhances the neurotoxicity of methamphetamine, amphetamine and MDMA. JNeurochem 2013; 125:102-110.
36. Carhart-Harris RL, King LA, Nutt DJ. A web-based survey on mephedrone. Drug Alcohol Depend 2011; 118:19-22.
37. Stuart D. Sexualised drug use by MSM: background, current status and response. HIV Nurs 2013; 13:6-10.
38. Dybdal-Hargreaves NF, Holder ND, Ottoson PE, et al. Mephedrone: public health risk, mechanisms of action, and behavioral effects. Eur J Pharmacol 2013; 714:32-40.
39. Miller ML, Creehan KM, Angrish D, et al. Changes in ambient temperature differentially alter the termoregulatory, cardiac and locomotor stimulant effects of 4-methylmethcathinone (mephedrone). Drug Alcohol Depend 2013; 127:248-253.
40. Shortall SE, Green AR, Swift KM, et al. Differential effects of cathinone compounds and MDMA on body temperature in the rat, and pharmacological characterization of mephedrone-induced hypothermia. Br J Pharmacol 2013; 168:966-977.
41. Lisek R, Xu W, Yuvasheva E, et al. Mephedrone ('bath salt') elicits conditioned place preference and dopamine-sensitive motor activation. Drug Alcohol Depend 2012; 126:257-262.
42. Gregg RA, Tallarida CS, McCurdy C, Rawla SM. Mephedrone (4-methyl-methcathinone), a principal constituent of psychoactive bath salts, produces behavioral sensitization in rats. Drug Alcohol Depend 2013; 133:746-750.
43. Aarde SM, Huang PK, Creehan KM, et al. The novel recreational drug 3, 4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharmacology 2013; 71:130-140.
44. Gatch MB, Taylor CM, Forster MJ. Locomotor stimulant and discriminative stimulus effects of 'bath salt' cathinones. Behav Pharmacol 2013; 24:437-447.
45. Marusich JA, Grant KR, Blough BE, Wiley JL. Effects of synthetic cathinones contained in 'bath salts' on motor behavior and a functional observational battery in mice. Neurotoxicology 2012; 33:1305-1313.
46. Huang PK, Aarde SM, Angrish D, et al. Contrasting effects of d-methamphe-tamine, 3, 4-methylenedioxymethamphetamine, 3, 4- methylenedioxypyrovaler-one, and 4-methylmethcathinone on wheel activity in rats. Drug Alcohol Depend 2012; 126:168-175.
47. Gregg RA, Tallarida CS, Reitz AB, Rawls SM. Mephedrone interactions with cocaine: prior exposure to the 'bath salt' constituent enhances cocaine-induced locomotor activation in rats. Behav Pharmacol 2013; 24:684-688.
48. Motbey CP, Clemens KJ, Apetz N, et al. High levels of intravenous mephe-drone (4-methylmethcathinone) self-administration in rats: neural consequences and comparison with methamphetamine. J Psychopharmacol 2013; 27:823-836.
49. Varner KJ, Daigle K, Weed PF, et al. Comparison of the behavioral and cardiovascular effects of mephedrone with other drugs of abuse in rats. Psychopharmacology (Berl.) 2013; 225:675-685.
50. Bauer CT, Banks ML, Blough BE, Negus SS. Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats. Br J Pharmacol 2013; 168:850-862.
51. Robinson JE, Agoglia AE, Fish EW, et al. Mephedrone (4-methylmethcathi- none) and intracranial self-stimulation in C57BL/6J mice: comparison to cocaine. Behav Brain Res 2012; 234:76-81.
52. Bonano JS, Glennon RA, DeFelice LJ, et al. Abuse-related and abuse-limiting effects of methcathinone and the synthetic 'bath salts' cathinone analogs methylenedioxypyrovalerone (MDPV), methylone and mephedrone on intra-cranial self-stimulation in rats. Psychopharmacol 2014; 231:199-207.
53. Weed PF, Leonard ST, Sankaranarayanan S, Winsauer PJ. Estradiol administration to ovariectomized rats potentiates mephedrone-induced disruption of nonspatial learning. J Exp Anal Behav 2014; 231:199-207.
54. Motbey CP, Karanges E, Li KM, et al. Mephedrone in adolescent rats: residual memory impairment and acute but not lasting 5-HT depletion. PLoS One 2012; 7:e45473.
55. Wright MJ Jr, Vandewater SA, Angrish D, et al. Mephedrone (4-methylmeth-cathinone) and d-methamphetamine improve visuospatial associative memory, but not spatial working memory, in rhesus macaques. Br J Pharmacol 2012; 167:1342-1352.
56. Zuba D, Byrska B. Prevalence and co-existence of active components of 'legal highs'. Drug Test Anal 2013; 5:420-429.
57. Aromatario M, Bottoni E, Santoni M, Ciallella C. New 'lethal highs': a case of a deadly cocktail of GHB and mephedrone. Forensic Sci Int 2012; 223:e38-e41.
58. Hunter LJ, Dargan PI, Benzie A, et al. Recreational drug use in men who have sex with men (MSM) attending UK sexual health services is significantly higher than in non-MSM. Postgrad Med J 2014; 90:133-138.
59. Prosser JM, Nelson LS. The toxicology of bath salts: a review of synthetic cathinones. J Med Toxicol 2012; 8:33-42.
60. Winstock A, Mitcheson L, Ramsey J, et al. Mephedrone: use, subjective effects and health risks. Addiction 2011; 106:1991-1996.
61. Kapitány-Fö vény M, Kertész M, Winstock A, et al. Substitutional potential of mephedrone: an analysis of the subjective effects. Hum Psychopharmacol 2013; 28: 308-316.
62. Cosbey SH, Peters KL, Quinn A, Bentley A. Mephedrone (methylmethcathi- none) in toxicology casework: a Northern Ireland perspective. J Anal Toxicol 2013; 37:74-82.
63. Levine M, Levitan R, Skolnik A. Compartment syndrome after 'bath salts' use: a case series. Ann Emerg Med 2013; 61:480-483.
64. Kolli V, Sharma A, Amani M, et al. 'Meow meow' (mephedrone) and catatonia. Innov Clin Neurosci 2013; 10:11-12.
65. Conway N, McGowan D, White D, Phillips S. Urinary retention secondary to mephedrone. BMJ Case Rep 2013. doi:10.1136/brc-2013-008816.
66. Rhidian R, Babu A. Acute kidney injury requiring haemodialysis following ingestion of mephedrone. BMJ Case Rep 2013. doi:10.1136/brc-2012-007974.
67. Sivagnanam K, Chaudari D, Lopez P, et al. 'Bath salts' induced severe reversible cardiomyopathy. Am J Case Rep 2013; 14:288-291.
68. Dorairaj JJ, Healy C, McMenamin M, Eadie PA. The untold truth about 'bath salt' highs: a case series demonstrating local tissue injury. J Plast Reconstr Aesthet Surg 2012; 65:e37-e41.
69. Russo R, Marks N, Morris K, et al. Life-treating necrotizing fasciitis due to 'bath salts' injection. Orthopedics 2012; 25:e124-e127.
70. Sutamtewagul G, Sood V, Nugent K. Sympathomimetic syndrome, chor-eoathetosis, and acute kidney injury following 'bath salts' injection. Clin Nephrol 2014; 81:63-66.
71. Winder GS, Stern N, Hosanagar A. Are 'Bath Salts' the next generation of stimulant abuse? J Subst Abuse Treat 2013; 44:42-45.
72. Schifano F, Corkery J, Ghodse AH. Suspected and confirmed fatalities associated with mephedrone (4-methylmethcathinone, 'meow meow') in the United Kingdom. J Clin Psychopharmacol 2012; 32:710-714.
73. Kesha K, Boggs CL, Ripple MG, et al. Methylenedioxypyrovalerone ('bath-salts'), related death: case report and review of the literature. J Forensic Sci 2013; 58:1654-1659.
74. Wyman JF, Lavins ES, Engelhart D, et al. Postmortem tissue distribution of MDPV following lethal intoxication by 'bath salts'. J Anal Toxicol 2013; 37:182-185.
75. Wright TH, Cline-Parhamovich K, Lajoie D, et al. Deaths involving methyle-nedioxypyrovalerone (MDPV) in Upper East Tennessee. J Forensic Sci 2013; 58:1558-1562.